![PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/df73d74a72129de1592255fc0a74db3d4b45eef3/2-Figure1-1.png "PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar")
PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations - Journal of Thoracic Oncology
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer - touchONCOLOGY
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer - Lung Cancer
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Lung cancer with MET exon 14 skipping mutation | LCTT
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Biomarkers in Lung Cancer: Integration with Radiogenomics Data | IntechOpen
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Diagnosis and Discussion -- Case 1068
PLOS ONE: MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
